鸡源致病性大肠杆菌的分离鉴定及药敏试验

为了解鸡源致病性大肠杆菌的生物学特性和耐药性,试验通过采集病料、细菌分离培养、16S rRNA基因鉴定、致病性试验、药敏试验等方法。结果表明:分离出的20株细菌的培养特征、镜检特征均符合大肠杆菌特征;16S rRNA基因序列经BLAST比对与大肠杆菌同源性达99.9%～100%,确定20株分离菌为鸡源大肠杆菌;20株大肠杆菌的致病力为40%～100%;10株鸡源致病性大肠杆菌对15种抗菌药物均呈现多重耐药,耐药率为33.3%～93.3%,耐药情况较严重和复杂。     

非嵌插类DNA结合药物的碱基序列特异性

本文讨论了非嵌插类DNA结合药物的碱基序列特异性,这对于探讨药物与DNA相互作用的分子机制是很有意义的。通过这些探索,得到了一些有意义的结果。     

反兴奋剂——奥林匹克永恒的课题

世界体坛兴奋剂泛滥成灾,玷污圣洁的奥林匹克运动。新的兴奋剂不断涌现,今IOC防不胜防。随着人类基因组计划的完成,人类遗传密码的破译,基因兴奋剂将很快产生,奥林匹克将面临极为棘手的课题,反兴奋剂斗争似乎永远无法停息。应当加大力度呼吁全世界人民提高对兴奋剂危害性的认识,杜绝研究、制造和使用兴奋剂。同时应当鼓励运动员人人从自我做起,拒绝使用兴奋剂,奥林匹克的圣火才能永放圣洁的光芒。     

系统药物学

系统药物学,是在系统水平认识药物,研究药物作用的系统性、多组分药物系统、和药物信息分子。系统药物学包括计算系统药物学、实验系统药物学及系统药物治疗学,需要引入新的思路、技术、算法与软件、设备等。中药现代化的方向是系统药物学,中药西化只是其组成部分之一。同时,要西药中化,西药中化与中药西化将成为构建系统药物学理论体系的重要组成部分。本文还讨论了系统药物学研究对药物发现和个性化治疗的意义。     

钙阻断剂与肿瘤治疗

抗药性是肿瘤化疗的最大障碍之一,具抗药性的肿瘤细胞药物外排功能很强,而钙阻断剂能抑制抗癌药物从抗药性肿癌细胞排出,导致细胞抗药性减弱,可用于肿囊化疗,有潜在的临床应用价值,但有副作用。故应寻求毒副作用小类似钙阻断剂的其他修饰物以促进肿癌化疗。     

中华鳖常见致病菌对13种抗菌药物的敏感性测定

本研究检测了13种抗菌药物对7株中华鳖致病菌的最小抑菌浓度（MIC），结果表明，从河南郑州的患病中华鳖体内分离的菌株较湖北武汉、湖北咸宁的病鳖体内分离的菌株对各类药物的敏感性强，而从武汉和咸宁产地的病鳖体内分离的菌株其对各类药物的敏感性也有很大差异，结果显示供试菌株对抗菌药物产生了不同程度的耐药性，推测滥用药物和用药方法不当是导致病原菌产生耐药性的原因。     

Multitasking with neurotensin in the central nervous system

The 13-amino acid peptide neurotensin (NT) was discovered over 30 years ago and has been implicated in a wide variety of neurotransmitter and endocrine functions. This review focuses on four areas where there has been substantial recent progress in understanding NT signaling and several functions of the endogenous peptide. The first area concerns the functional activation of the high-affinity NT receptor, NTR-1, including the delineation of the NT binding pocket and receptor domains involved in functional coupling to intracellular signaling pathways. The development of NT receptor antagonists and the application of genetic and molecular genetic approaches have accelerated progress in understanding NT function in several areas, including the involvement of NT in antipsychotic drug actions, psychostimulant sensitization and the modulation of pain, and these are reviewed in that order. There is now substantial evidence indicating that NT is required for certain antipsychotic drug actions and that the peptide plays a key role in stress-induced analgesia.Received 18 March 2005; received after revision 9 May 2005; accepted 23 May 2005     

Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development

Phosphodiesterases (PDEs) are essential regulators of cyclic nucleotide signaling with diverse physiological functions. Because of their great market potential and therapeutic importance, PDE inhibitors became recognized as important therapeutic agents in the treatment of various diseases. Currently, there are seven PDE inhibitors on the market, and the pharmacological and safety evaluations of many drug candidates are in progress. Three-dimensional (3D) structures of catalytic domains of PDE 1, -3, -4, -5 and -9 in the presence of their inhibitors are now available, and can be utilized for rational drug design. Recent advances in molecular pharmacology of PDE isoenzymes resulted in identification of new potential applications of PDE inhibitors in various therapeutic areas, including dementia, depression and schizophrenia. This review will describe the latest advances in PDE research on 3D structural studies, the potential of therapeutic applications and the development of drug candidates.Received 30 November 2004; received after revision 24 January 2005; accepted 5 February 2005     

A pathway profile-based method for drug repositioning

Finding new applications for existing pharmaceuticals,known as drug repositioning,is a validated strategy for resolving the problem of high expenditure but low productivity in drug discovery.Currently,the prevalent computational methods for drug repositioning are focused mainly on the similarity or relevance between known drugs based on their "features",including chemical structure,side effects,gene expression profile,and/or chemical-protein interactome.However,such drug-oriented methods may constrain the newly predicted functions to the pharmacological functional space of the existing drugs.Clinically,many drugs have been found to bind "off-target"(i.e.to receptors other than their primary targets),which can lead to undesirable effects.In this study,which integrates known drug target information,we propose a disease-oriented strategy for evaluating the relationship between drugs and disease based on their pathway profile.The basic hypothesis of this method is that drugs exerting a therapeutic effect may not only directly target the disease-related proteins but also modulate the pathways involved in the pathological process.Upon testing eight of the global best-selling drugs in 2010(each with more than three targets),the FDA(Food and Drug Administration,USA)-approved therapeutic function of each was included in the top 10 predicted indications.On average,60% of predicted results made using our method are proved by literature.This approach could be used to complement existing methods and may provide a new perspective in drug repositioning and side effect evaluation.     

Preparation and cellular uptake of PLGA particles loaded with lamivudine

Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles loaded with lamivudine and coated with bovine serum albumin (BSA) were prepared via a double emulsion method. The influences of experiments parameters such as volume of inner aqueous phase, concentration of organic phase and ultrasonication time on the particle size and drug entrapment efficiency were investigated, obtaining PLGA particles with a diameter of ~260 nm and drug entrapment efficiency of ~35%. The particles were observed by scanning electron microscopy and transmittance electron microscopy, showing a core-shell structure. BCA assay found that 58 mg BSA was present on/in 1 g LPB particles. The loaded lamivudine showed a burst release at beginning and sustained release until 24 h in physiological conditions. Low pH could accelerate the release of lamivudine from PLGA particles, making the PLGA particles potential intelligent intracellular drug carriers. The PLGA particles were readily internalized into the human liver cells within a short time and increased gradually with the prolongation of incubation time regardless of the loading of lamivudine. The particles either resided within lysosomes or transferred to cytoplasm, but could not enter into the cell nucleus. The cell viability was not significantly influenced in the presence of the particles regardless of lamivudine encapsulation, suggesting that this kind of particles may be a good candidate for the intracellular anti-hepatitis B drug delivery.